Submissions

The journal uses an online submission system available at Elpub and accepts manuscripts in Russian or in English that meet the requirements of the Editorial Policies and Author Guidelines.

Manuscripts are published after successful peer review and approval by the Editorial Board (see the Editing and Publishing Process Flowchart). The journal publishes manuscripts on an unpaid basis .

For more details on the submission process and communication with the editorial staff, please see the corresponding sections below.

Submission of a manuscript to Safety and Risk of Pharmacotherapy implies the following:

The manuscript has not been published before.
It is not under consideration for publication elsewhere (controlled by Antiplagiat plagiarism checker).
The submitted materials do not violate any third-party rights or current legislation.
The authors have read the Scope, Publication Ethics & Malpractice Statement, and Editorial Policies of the journal.
When drafting the manuscript, the authors adhered to ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. The authors meet the four mandatory ICMJE criteria for authorship, including: 1) substantial contributions to the study concept, design, analysis, and/or result interpretation; 2) drafting the manuscript and substantive (logical) editing; 3) checking the final version of the manuscript prior to publication, and 4) accepting responsibility for the work as a whole and for each individual element, as well as the ability to respond promptly to editorial enquiries before and after publication.
Each author checked the spelling of their names in Russian and English ( according to ORCID), their affiliation, correct ORCID number, as well as its up-to-date status of completion.
The authors have appointed a corresponding author, to whom they delegate the primary responsibility for communication with the journal.

II. Manuscript submission and interaction with the journal

To submit a manuscript, the authors need to register on the journal’s website (https://www.risksafety.ru), fill out the online form, and upload the article; scanned copy of a referral from the institution (cover letter); scanned copy (as one file) of ICMJE Disclosure of Interest filled out by all the authors, and additional documents and supplements to the manuscript (e.g. illustrations, original research data and algorithms, proof of permission to publish borrowed figures when required, etc.) in Start submission.

Only original cover letters should be mailed to the Editorial Board at 8/2 Petrovsky Blvd, Moscow 127051, Russia (127051, Москва, Петровский б-р, д. 8, стр. 2), attn: O.F. Fedotova, Managing Editor. If the authors represent different institutions, each institution provides several cover letters.

Before submitting the manuscript, it is highly recommended to control its progress using Author’s checklist for compliance with the Journal policies.

The journal does not require copies of

ethics committee decisions
patient informed consents for publication
permissions to mention contributors in the Acknowledgements section

Communication between the journal and the author

The editorial staff communicate with the authors with the help of the corresponding author they have selected. See the process a manuscript goes through in the electronic editorial office in the Editorial and Publishing Process flowchart.

All submitted manuscripts are pre-evaluated for compliance with the Author Guidelines (including the requirements for Borrowings and plagiarism). If a manuscript does not fulfil the requirements, it may be returned to the author for correction. At this stage, a manuscript may also be rejected if it is not in line with the aims and scope of the journal or lacks originality. The executive secretary of the journal or Editor-in-Chief decides whether to accept or reject a manuscript.

After checking for compliance, the editors send the manuscript for peer review. The peer-review period takes two (2) weeks to two (2) months. In case of dispute, the editorial staff may ask several additional experts to review the manuscript. Copies of the reviews are sent to the authors for their information.

Having received two positive reviews, the manuscript is sent to its editor who will prepare it for publication. If the reviewers and/or editors made any comments, the authors are to make all the necessary corrections within 14 days. If the authors fail to submit the corrected version within one (1) month, the editorial staff have the right to withdraw the article from publication, of which the corresponding author will be duly notified. In this case, the authors may resubmit the manuscript to the journal, and it will again undergo the full preparation process. The Editorial Board makes a final decision on publication of the manuscript or its rejection.

If the manuscript is accepted for publication, the authors will be sent the final version of the article (a proofread) for approval. The authors have to reply within two (2) days. If the authors do not reply, the article is considered approved.

You may find information on manuscript rejection rates and the average turnaround from submission to publication in the Main Info about Journal section.

Revision of the editors’/reviewers’ decisions

The authors may challenge the decisions if they disagree with the conclusions or some remarks of the reviewers and/or the editorial staff. To do this, the authors will have to provide written arguments for each remark and send an email to the editorial staff.

The journal encourages resubmission of manuscripts that are potentially acceptable but were rejected due to the lack of major revisions or additional data. The editorial staff will provide a detailed explanation of what should be corrected for the manuscript to be accepted for publication.

Actions taken by the editorial staff upon discovery of plagiarism, data adulteration, or fabrication

In case the editorial staff discover any research misconduct on the part of the authors, including plagiarism and data manipulation or falsification, the journal adheres to the principles of COPE.

Within the context of Safety and Risk of Pharmacotherapy, “misconduct” implies to any actions of researchers, including mistreatment of test objects, or intentional manipulation of research data so that these data no longer reflect the observations, as well as any actions of the researchers that do not comply with ethical and scientific standards.

Safety and Risk of Pharmacotherapy does not classify as research misconduct: honest mistakes; unintentional discrepancies in planning, conduction, interpretation, or assessment of research methods or results; or misconduct not affecting the research.

If plagiarism, data adulteration or fabrication is discovered at any stage of article preparation, the Editorial Board will consider rejection of the manuscript.

Correction of mistakes and retraction of an article

If an article is found to contain mistakes that affect perception but do not distort the research results, these mistakes may be corrected by replacing the pdf version of the article (with mistakes highlighted in the pdf file and on the journal’s web page).

If there are mistakes confounding the research results or plagiarism/research misconduct related to data adulteration or fabrication, the article may be retracted. The retraction may be initiated by the journal, an author, an organisation, or a private individual.

The retracted article is labelled RETRACTED, and the reason for retraction is shared on the article’s web page. Indexing databases are notified of retraction. For more information on the peer review process, possible author replacements, ethical oversight, complaints, appeals, and post-publication corrections, please see the relevant sections on the journal’s Policies page.

III. Article types

Clinical practice guidelines / expert consensus

Systematic review and meta-analysis

Narrative review

Review to evaluate the benefits, risks, safety, and efficacy of a medicinal product

Original research / papers

Brief communication

Survey

Controlled clinical trial

Case report and case series

Interview

Editorials

Commentaries and Counterpoint articles

Clinical practice guidelines / expert consensus

Volume: up to 9,000 words

Generally, clinical practice guidelines are a result of the journal’s close cooperation with national and international professional associations. The guidelines published in the journal are subject to evaluation using the Appraisal of Guidelines for Research & Evaluation (AGREE) II tool or the Delphi approach.

Since often the format of the original national guidelines differs from that of international guidelines (for example, Russian versions do not have an abstract), the journal and the authors make every effort to create an abstract in English maximally adapted to the AGREE and RIGHT requirements, for better indexing and visibility in international databases.

Suggested guidelines:

Systematic review and meta-analysis

Volume: up to 9,000 words (all sections of the manuscript)

This type of publication is a systematic critical analysis of literature and data sources on a clinical topic, with a focus on causes, diagnosis, prognosis, therapy or prevention of a condition, and further data generation in order to address the research question or hypothesis. All literature or data sources should be systematically selected, screened for inclusion and evaluated. Describe the search and selection process in the Materials and Methods section. The authors of a meta-analysis add the specific type of study or analysis, population, intervention, exposure, tests, and results for each publication or data source to ensure that the analysed materials are homogeneous. Data sources should be as relevant as possible. Ideally, the search should take place within a few months prior to manuscript submission.

For meta-analyses of randomised controlled studies, the authors are required to provide the PRISMA flowchart and checklist.

For meta-analyses of observational studies, the authors are required to provide the MOOSE flowchart and checklist.

At least 50 references should be used, including studies issued within the last three (3) years.

Suggested guidelines:

Narrative review

Volume: up to 6,000 words (all manuscript sections)

Narrative reviews are systematic analyses of the current literature, most often with the aim of bringing forth a new classification or substantiating controversial and/or innovative hypotheses, with clear conclusions. The journal requires the reviews to be clearly structured and to have a system of subheadings. The journal establishes the following three (3) mandatory sections for a review article:

Introduction:a brief overview of the topic background information on what is known/ controversial), a plausible hypothesis to be proved, and the search strategy (databases, keywords and search period covered).
Main part: literature analysis and discussion. This part must have a structure and subheadings. Continuous text is not accepted in the main part. The authors should:

compare approaches, methods, and results
detect trends, discrepancies, and study gaps
critically assess source quality and reliability

Conclusion: main conclusions, potential limitations, clinical significance, directions for future research.

Use several databases for systematic search. (Systematic) reviews based only on a Russian/foreign database will be rejected. Please see the list of recommended databases below.

Since a systematic review requires analysis and synthesis of novel data, rather than paraphrasing the known information, the authors are advised to visualise their work as much as possible using tables and figures. If reused, properly reference graphical materials. If taken from sources distributed under a licence other than CC BY, graphic materials should be accompanied by a notice "used with permission of the copyright holder".

The title indicates the type of article at the end (please state that the article is a review after a colon). The references should list not less than 40 publications issued within the last three (3) years. For quality assessment of narrative review articles, we recommend using SANRA checklist.

To avoid a common mistake, literature analysis in a review is used as a method, rather than a goal, to answer the study question. Unacceptable are literature reviews that are a simple compilation (copying text fragments from the publications) or narration of the published studies without an explicit analysis.

Suggested materials:

Review to evaluate the benefits, risks, safety, and efficacy of a medicinal product

Volume: up to 6,000 words (all manuscript sections)

This type of review aims to provide an independent safety assessment of a particular medicinal product and the best practices for its use. The title should sound objective and unbiased (no advertising), and the product should be referred to by its INN (International Non-proprietary Name). The abstract structure should follow the logic of the main part.

The following structure is recommended for the full text:

Introduction: justification of the topic relevance (e.g. incidence and prevalence of a disease, the unmet medical needs, and the existing treatment guidelines (with an emphasis on regional differences, when appropriate)); background to the development and use of the medicinal product. At the end of Introduction, include the study aim justifying the whole work.
Main part: mechanism of action, including pharmacokinetics and pharmacodynamics data; clinical use, including efficacy data

Safety assessment. This section should form the main part of the review: safety in clinical trials; post-marketing data; safety in special populations (including pharmacogenomics data, if any)

Comparisons with other medicinal products. Data comparison in a table, if appropriate.

Conclusion: analysis and interpretation of the data presented in the review; up to 3,000 words and up to 100 references

References – at least 30, including those published over the last three (3) years.

Original research / paper

Volume: up to 6,000 words (all manuscript sections)

These are designed to present original unpublished research findings that contribute novelty to clinical or experimental practice and can be subsequently replicated and generalised (based on the study design specified in the manuscript and detailed description of methods). Original studies have many types and formats depending on their aim, design, and other characteristics. For example, they include brief communications, prospective and interventional studies, surveys, and randomised controlled trials (RCT). For the convenience of the authors, original research papers are categorised according to international guidelines, established practice, and the journal scope.

The formal structure of the full text and abstract of an original research paper should correspond to the chosen research design (EQUATOR Network guidelines). The most common structure is the IMRAD style, including Introduction, Aim, Materials and Methods, Results, and Discussion sections (Conclusions section is acceptable). The editorial staff recommend using subheadings, especially in the Discussion section (where the authors outline the novelty, clinical significance, study limitations, recommendations for follow-up research, and most importantly, if possible, the role of their study in the context of existing studies). This type of publication should clearly state the research question or the hypothesis. Make Materials and Methods detailed for higher reproducibility. The authors are encouraged to register study protocols (see clinicaltrials.gov) and post the source data in public repositories. Discussion/ Conclusions clearly word clinical relevance and study limitations.

Suggested materials:

For interventional studies,the Materials and Methods section should be as detailed as possible in accordance with the TIDieR-Checklist and the relevant guidelines.
For diagnostic/prognostic studies (prospective studies designed to develop, validate, or update the diagnostic or prognostic accuracy of a test or model), STARDand TRIPOD guidelines should be used.
For randomised controlled trials, the appropriate CONSORT checklist and its variants/supplements should be used (see the Clinical Trials below and CONSORT updates).
For experimental in vivo studies, the authors should consider the layout and the coverage of issues according to ARRIVE guideline. A detailed explanation and relevant checklists can be found at the ARRIVEresource portal.
For all clinical and experimental studies involving only one gender, the manuscript title and the Discussion section should reflect this, according to SAGER
Please find Original article template
For Observational Studies in Epidemiology (STROBE), please use relevant checklist available at EQUATOR Network.

Brief communication

Volume: up to 2,000 words (all manuscript sections)

This type of publication represents a brief report that may include:

Preliminary study data with anticipated findings that warrant a more definitive study.
Replication studies based on known protocols that partially complement previously published studies.
Studies on important topics that report negative results.

These articles should have structured text, up to two (2) tables, and up to two (2) figures. When designing, conducting, and writing a "feasibility assessment of...", which is the most common topic for brief communications, the authors should use the How We Design Feasibility Studies guideline, which discusses 8 feasibility criteria and often adds safety as a 9th criterion.

Survey

Volume: up to 6,000 words (all manuscript sections)

Manuscripts reporting survey data, such as studies involving patients, clinicians, the public, or others, should report data as novel as possible, ideally collected within the past 2 years. Survey studies should have sufficient response rates (generally, at least 60%) and appropriate description of non-responders to ensure that non-response bias does not threaten the validity of the findings. For most surveys, such as those conducted by telephone, personal interviews, mail, e-mail, or online, the authors are encouraged to report survey outcome rates using standard definitions and metrics, such as those by the American Association for Public Opinion Research. In addition, the authors should submit the survey instrument, if possible, as a separate file that may be considered for publication online as a supplement to the article. Posting raw data and algorithms in public repositories is also encouraged.

Suggested guidelines and materials:

Controlled clinical trial

Volume: up to 6,000 words (all manuscript sections)

This type of publication is designed to present clinical trials with a control group. The text layout should typically include Introduction, Aim, Materials and Methods, Results, Discussion, and Conclusions. It is recommended to use subheadings, especially in the Discussion section. Discussion should clearly state clinical relevance and study limitations. The topical material and methods should be carefully detailed for higher reproducibility. This type of publication requires a structured abstract, including Introduction, Aims, Materials and Methods, Results, and Conclusions (Discussion not included).

For randomised clinical trials, the editorial staff recommend pre-registering study protocol (e.g. on clinicaltrials.gov) and posting the raw data in public repositories.

Suggested guidelines:

Case report (clinical observation) and case series (observations)

Volume: up to 4,500 words (all manuscript sections)

This article type should describe unreported or rare adverse drug reactions (substantiated by an appropriate literature search and analysis and reflected in the Introduction and Discussion sections).

The journal does not accept clinical cases structured as a lecture demonstrating known medical interventions and outcomes.

Abstract structure:

Introduction: briefly (1–3 sentences) justifies publication of the given clinical case.
Case report: briefly describes the case 1) clinical diagnostics methods (if applicable); 2) major clinical, laboratory, instrumental and other parameters, precise numbers, medical interventions and/or disease outcomes (if applicable); 3) health facility where the case was observed (with observation period).
Conclusions:fully meet study objectives and show applicability of the results. The conclusions should cover a specific case, while their extrapolation to larger patient groups require caution.

Essential elements of this publication are:

a rigorous literature review substantiating the adverse drug reaction observed for the first time or described in similar publications and subsequent discussion
a detailed picture of the patient’s follow-up from admission to discharge supplemented with some form of visualisation (e.g. figures and tables)
a section (statement) on obtaining consent for publication from the patient (or their legal representatives). If it is not possible to identify the patient using the submitted medical history and photographs and, thus, the patient’s consent is not required, please add a statement to that effect

The journal does not require the authors to provide a copy of the completed consent form, nor does it require this consent form to meet any standards. However, for the convenience of the authors, the journal provides a List of items commonly found in such consent forms.

The expected number of references is at least 15, preferably over the last three (3) years.

Suggested guidelines and materials:

Interview

The journal editors conduct interviews with the leading experts in pharmacy, medicine, and public health on current issues, promising research, and innovations. The interviews can be conducted in person, by e-mail, or by telephone. This publication type requires a photograph of the interviewee (high quality, preferably business style). The final text of the interview is always agreed with the interviewee before publication.

Editorials

Editorials are short publications on relevant issues written by the leading experts in a specific subject area upon a request from the Editorial Board. The main aim of this type is to express the author’s opinion and personal view on a current topic (e.g. development and use of innovative medicines or discussion of various therapeutic strategies that are under study and may deepen the readers’ professional knowledge). The title should include no brand names of medicinal products. No abstract is required. An editorial should include a small introduction with background information on the study field. Preferably, the main part should contain a numbered list of the issues. These may include the following:

What are the main research directions and prospects in this field at this time?
What is the potential and ultimate goal of this research? What is needed to achieve this goal?
How do the authors see the development of the field in the coming years?

The authors of this type of publication may use a maximum of 15 references, two (2) tables and two (2) figures. Avoid using unpublished data; the authors should obtain written consent from the cited individuals to use unpublished results or personal communications in the manuscript. The journal encourages highlighting the top references (authors' choice).

Commentaries on published articles and responses to commentaries

Commentaries are provided as reasoned feedback that addresses scientific, methodological, ethical, or clinical aspects of the materials published in the journal, as well as their interpretation. Commentaries are accepted no later than two (2) months from the publication date. Whenever possible, commentaries of the Editorial Board are published together with the response by the authors of the initial article. As an exception, a commentary and a response may be published in the issue after the next one. Only one round of commenting and responding is allowed, without continuing the discussion in subsequent issues of the journal. Commentaries and responses are required to include the References section, including 2–10 items, where the commented article or commentary should be cited, as well as sources supporting the arguments of the opponent.

When making a decision to publish, preference is given to commentaries on articles labelled "Editors’ Choice". If possible, commentaries accepted by the Editorial Board are published together with the response of the authors of the original article to this commentary.

Title guidelines:

A commentary title should include the original title of the commented article in quotation marks, preceded by the phrase and a colon "Commentary on the article:…" and followed by the first author of the original article.
A response title should include the title of the commentary with the addition of "Response to commentary:…" at the beginning.

IV. Structure of bibliographic data / metadata

Bibliographic data of an article (including the title, names and ORCID profiles of its authors, the abstract etc.) are metadata used for correct indexing of the article in Russian and international databases, and library collections. Bibliographic data are also used for DOI generation. Therefore, these data should also be provided in English.

Correct indexing, potential visibility, and citability of an article depend on reliability and completeness of the bibliographic data presented by its authors. For example, if an author spells their name differently from the variant used in their ORCID profile, the publication will not show in their record automatically. If authors do not mention a standard study design in the title or abstract, their paper might not be included in a systematic review that only considers studies of a particular design. Databases will not be able to index an article correctly and completely if the abstract does not specify the international non-proprietary names of the studied medicinal products; the administration methods used; the pathological condition of interest; or the sex, age, and other patient characteristics. This will reduce the chances of finding the article for potential readers.

Structuring bibliographic data in the order they appear in the manuscript

UDC (Universal Decimal Classification). It is provided in upper left-hand corner of the first page of the manuscript. The authors should select the UDC code based on the subject of the article.

Manuscript title. The title should correspond to the content of the article, be informative, and fully reflect the main aim set by the author for covering the topic. The title should not include hollow and meaningless science-like words (e.g. About the issue of studying… or Modern aspects of…). The title should not contain acronyms or abbreviations except for those listed in the MeSH (Medical Subject Headings).

Specify standard study designs at the end of the title after a colon (e.g. “randomised controlled study”, “systematic review”, or “case report”).

The title of a manuscript should not exceed 13 words.

Author initials and last names. The authors submit their full name in English according to their ORCID profile (published name). When filling in their published name in the ORCID profile in the first place, the authors should use the most common spelling from their previous publications. Full names in English should be laid out as follows: first name, the initial of the patronymic, and last name (Ivan I. Ivanov). The order of authors’ names in their publications is decided upon by the authors. The corresponding author responsible for all correspondence of the authors with the editorial staff and the readers should be indicated with an envelope symbol in superscript to the right of their last name.

Author affiliations. An affiliation of an author should specify the full official name of the organisation (according to the Charter) and its postal address (street, house number, city, zip code, and country). The journal allows for multiple affiliations; please list all employers relevant to the research. If the authors of a manuscript are from different institutions, the affiliations of each author to a particular institution should be indicated in superscript. For correct indexing in international citation databases, please do not include quotation marks or the legal form and departmental affiliation of your institution.

ORCID profiles. The Editorial Board recommends that each author uses and annually updates their ORCID profile. An ORCID profile helps to correctly author index the author in databases (one click to a complete and up-to-date report on their scientometric indicators), automatically addpublications (autocompletion) to the author’s ORCID profile (as well as other profiles), and provide readers with comprehensive author credentials and the author’s expertise. Therefore, a minimally completed ORCID profile is required from the corresponding author. Give the full author’s name in English only.

Corresponding author. As stated above, repeat the name in the footnote, including full name and an e-mail (preferably corporate). This author corresponds with the editorial staff on behalf of the authors, and later exchanges emails with the readers.

Abstract. The abstract includes 150–300 words. It describes the content of the manuscript as detailed as possible. Abstracts of original papers, reviews, and brief communications should be structured according to the type of article, as described above. Generally, a brief description of the topic relevance should be followed by separate subsections succinctly summarising the aim of the work, materials and methods, results, discussion, and conclusions. The subheadings of these sections should be marked in bold (see article templates: Review, Original Paper, and Case report). The abstract should not include any references. The editorial staff recommend against using abbreviations and acronyms (except for those contained in the MeSH thesaurus). If a registered study protocol is available (especially for randomised controlled trials), it should be mentioned at the end of the abstract under the heading REGISTRATION as follows:

REGISTRATION: Clinicaltrials.gov identifier: NCT03945968. Registered: 10 May 2019.

Keywords are the most significant words or word combinations on the topic of research, reflecting the topic specifics, study objects, and results. Keywords are used to search for articles in databases. The list of keywords should include 5–12 words or word combinations that complement the summary and title of the article. There should be no more than three (3) words in one word combination. Words in a word combination should not be separated by a comma. Quotation marks should not be used. Keywords should be given in the nominative case and separated by a semicolon. There should be no full stop after the keywords. For selecting keywords in English, the editorial staff recommend using the MeSH thesaurus of medical terms.

Bibliographic data for citation. Please use the following template:

Petrov V.I., Ryazanova A.Yu., Tokareva N.S. Analysis of the consumption of medicinal products associated with a high risk of drug-induced liver injury in patients with COVID-19. Safety and Risk of Pharmacotherapy. 2024.

Upon acceptance for publication, the editorial staff will supplement these data with relevant details.

V. Contents of the main text sections

As stated above for the basic article types, the layout of the main part may vary considerably depending on the study design and the applicable EQUATOR Network guidelines. However, these sections generally retain the same structure: introduction, aim, materials and methods, results, discussion, and conclusions.

The authors should emphasise the following parts.

Introduction

The section should include a brief assessment of the current state of research on the topic.
The section should explain the novelty, importance, and aim of the study.

Aim

The section should explain what the research purpose is. It should describe the research question or the hypothesis being proved (if the aim of the study is to prove a hypothesis).
If the study tested the null hypothesis, this should be stated.
The aim should be consistent with the title and the conclusions.
This section may also list additional objectives.

Materials and methods

This section is required for original articles.
It should describe the materials, study objects, and methods in sufficient detail to allow for reproduction of the study.
The choice of experimental objects should be justified. The Materials and Methods section should specify the number of participants and the methods of their selection (inclusion/exclusion criteria).
Sources of all animals, cell cultures, strains etc. used in the study should be specified accurately and in detail. The Materials and Methods section should specify the purity qualification and manufacturer of the reagents used, as well as the brand and manufacturer of the instruments and equipment used in experiments.
Company names should be given in their original spelling.
Where possible, the international non-proprietary names of medicinal products is preferred over their trade names. Articles on clinical trials should give information on ethics committee approval (with the name, date, and number of the approval document).
Studies involving human subjects should include an indication of compliance with the 2013 Declaration of Helsinki.
It should be made clear what types of consent were obtained (e.g. for participation in the study, for publication of anonymised data etc.).
The section specifies the number of patients who withdrew from the study.
Research involving animals should include an indication of compliance with international, national, or institutional animal welfare regulations.
Specify the conditions and sequence of operations in the experiments and the software used in the study.
It is not necessary to describe well-known methods in detail; a relevant reference will suffice.
This section should detail the randomisation process.
Specify the methods used for blinding and statistical processing of results.
Describe the statistical methods used: software, statistic methods, design principles, sample size, and statistical criteria.
If an AI-based software was used for drafting the manuscript, the name and version of the software should be given, as well as the prompts. Example:While preparing this study, the author(s) used [TOOL/SERVICE NAME] in order to [THE REASON]. After using this tool/service, the author(s) have reviewed and edited the content as needed and assume full responsibility for the publication content.

Results

The authors should list the major results, no matter how much they support or contradict study hypothesis and other studies. Detailed requirements:

Present the results in the same order as the methods described.
Provide baseline and endline data for the sample.
Specify all absolute values (e.g. increase, decrease, or absolute difference between groups), effect sizes, and appropriate measures of uncertainty, such as confidence intervals (CIs).
Include mean values and standard deviations for normally distributed data, as well as medians and ranges or interquartile ranges (IQRs) for data that are not normally distributed.
Avoid using solely results of statistical hypothesis testing, such as P-values that cannot convey important quantitative information.
In most studies, p-values should follow comparison of absolute values or measures of uncertainty (e.g. 0.8%, 95% CI: -0.2 to 1.8%; P=0.13).
Avoid presenting isolated p-values, without the data being compared. Approaches such as calculating number of treatments per unit of benefit may be mentioned, if appropriate. Relative risk measures (e.g. relative risk, risk ratios) may also be reported and should include CIs.
Studies of screening and diagnostic tests should report sensitivity, specificity, and likelihood ratios observed.
If a prognostic value or accuracy is reported, the prevalence or pre-test probability should also be reported.
All randomised clinical trials should include results obtained from analyses of treatment prescription and side effects.
All descriptions of surveys should include response rates.
No personally identifiable information (patient names and initials, medical record numbers) may be published. Photographs submitted for publication should not provide for patient identification.

The journal encourages pre-posting all raw research data in public repositories that assign DOIs (e.g. Mendeley Data).

Discussion

Discuss the results in comparison with other publications.
Give possible explanations of similarities/ contradictions with other studies.
List the limitations the study faced.
Discuss whether the results meet the study hypothesis.
Offer practical applications.
Give recommendations for future research.

Conclusion(s)

This section includes only conclusions directly supported by the results.
Put equal emphasis on positive and negative findings of equal scientific value.
Describe importance and clinical relevance of the study without speculating or overgeneralising.
Explain, if necessary, whether additional research is required to begin using the obtained information in a clinical setting.

This section may present the findings as a numbered list. In this case, it should be called Conclusions.

VI. Text layout and formatting

Formatting

upper and lower margins: 2 cm, left: 3 cm, right: 1.5 cm.
type: 14-point Times New Roman with 1.5-line spacing (main text); 12-point Times New Roman with 1-line spacing (abstract, keywords, data for citation, corresponding author data, tables, figure captions, acknowledgements, disclosure statement, reference list, and information about the authors)
paragraph indention: 1.25 mm; avoid using space bar and tab key
avoid hyphenations; turn off automatic hyphenations

Abbreviations and glossaries

Abbreviations are allowed in the manuscript if written out in full at the first mention.
Explain abbreviations given in the abstract once again in the body text.
Common abbreviations (e.g. DNA, COVID-19) do not need explanation at first mention.
The manuscript may be provided with a glossary of terms and abbreviations, placed at the beginning before the Introduction section.
When using an abbreviation less than three (3) times, replace it with the full term.

Units of measurement

Units of measurement and other numerical values should be given according to the SI system.

Citations

Citations should be verified and properly formatted.
References to literature sources in the text should be numbered in square brackets [1,2].
References should be numbered consecutively in the order in which they are first mentioned in the text.
Non-indexed sources (see the Literature section) should be referenced in footnotes.¹
References in the body text including names should start with initials followed by last names (According to P.M. Ivanov et al. [25], as well as J.K. Johnson et al. [26]).
Foreign last names should be spelled as in the source publication.
When citing preprints, the authors of the manuscript should note "preprint" in parentheses in the most appropriate place in their opinion (according to P.M. Ivanov et al. [25] (preprint)).

Full stops

Do not put a full stop after the title manuscript; subheadings; keywords; links; titles, notes, and captions of tables and figures; measurement units (e.g. с, seconds; г, gram; мин, minute; сут, day; град, degree), some numerals (млн, million; млрд, billion; трлн, trillion), subscripts (Т_пл_,melting point; T_ф_._п_, phase transition point).

Latin names

Use generally accepted taxonomy nomenclature for Latin names of research objects; binomial names of species and higher taxa are usually typeset in italics (e.g. Valeriana officinalis, genus Valeriana, family Valerianaceae).
Genus and species names should be given in full at the first mention in the text; then the generic name may be indicated by one (first) capital letter, and the species name should be written in full (e.g. officinalis).

Names and symbols

Names and symbols of genes should be in italics, and names of gene products should be in regular font and start with a capital letter, e.g. genes: fos, c-myc, ATM; proteins: Fos, c-Myc, ATM.
Names of mobile genetic elements and the first three letters of restriction sites should be in italics, e.g. hobo-element, HindIII

Names of phages and viruses are written in Latin (regular font).

VII. Tables and figures

All tables and pictures included in the manuscript should be mentioned in the text and appear in order of mention. Table data and figure captions should not repeat the same information.

Tables

Tables include editable text and should be created in Microsoft Office applications. Each table should have a title that includes its number and name, e.g.: Table 2.Description of vital processes.
No full stop is used at the end of the table’s heading.
Russian text in tables should be given together with an English translation.
Place translated title below the title in Russian.
Headings are aligned to the left. Tables are numbered using Arabic numerals in order of appearance in the text. If there is the text has the only table, it should still be numbered.
References to the tables are made as follows: “Table 3 shows that…” or “It is indicated... ( 3)”. Headings of columns and rows should be highlighted in bold.
There should not be any empty cells in tables. If the authors have no data to put in a cell or there are other reasons for a cell to be empty, the authors should make a note to that effect in this cell or in the note to the table.
It is not recommended to use abbreviations in tables, but if they are necessary, their interpretation should be given in the note to the table.
All data presented in tables should correspond to those in the text of the article.

Figures

Each figure should have a caption that includes its number and title, for example: 2. Description of vital processes
There is no full stop at the end of a caption.
Figures are numbered using Arabic numerals in order of their appearance in the text. If there is only one picture in the text, it should still be numbered.
Figures should be referenced in the text as follows: “Figure 3 shows...” or “It is shown... (3)”.
Graphs and photographs should have a clear legend (descriptive text) that explains the meaning of the figure without the need to read the full manuscript.
The authors should use vector formats (svg, al, eps, cdr) but may use raster formats (jpg, tif), as well as pdf. Provide separate files for these illustrations (e.g. photographs, scanned figures, and screenshots) in jpeg2000 or tiff formats, with minimal resolution 300 dpi, without compression.
Any graphs and charts (with numerical data) should be made using Microsoft Excel 2003 and later and placed in linked documents or provided as separate files in XLS or XLSX formats (with places where the figures should appear marked in the manuscript).
In the case of using third-party spreadsheet processors and specialised plotting/ charting software, provide either a screenshot or a copy for a virtual printer in pdf (preset to Press Quality) or other vector format.
All graphs and figures should be designed to be fully accessible to colour-blind readers (e.g. by introducing different numbers/letters/symbols for curves or areas presented in different colours).
Avoid using a pie chart (replace it with a line chart, as it would illustrate the values more clearly).
Avoid using coloured backgrounds, shadows in line graphs, or 3D graphics inappropriate for two-dimensional figures.
Add internal scale markers and staining method for micrographs.

For reused figures, ensure the correct attribution (either in the text or in the figure caption). If a borrowed figure is distributed under a licence other than CC BY, which implies the use of content without permission of the copyright holder, the authors of the manuscript should request permission from the corresponding author of the original publication; make sure to add the source and the licence.

VIII. Mathematical formulae, equations, and symbols

Stand-alone mathematical formulae (placed on a separate line) should be generated as a single MathType element.
MathType equations should use the software’s default settings for font type, size, and placement of symbols.
Digits should be in regular font; Latin letters (alphabetical symbols) denoting values should be in italics; abbreviated mathematical symbols (e.g. sin, cos, lg, lim, max) should be in regular font; Russian and Greek letters (both in formulae and subscripts/superscripts) should be in regular font; subscripts/superscripts should be in regular font—e.g. N_fin(i.e. N_final), C_max, S_mean—with no full stop at the end.
Formula formatting as sets of different elements, such as a table, a text, or a filled-in box, is unacceptable.
The article should not contain any formulae formatted as images.
Simple mathematical and chemical formulae (e.g.a₂+ b₂= c₂; H₂SO₄) and individual variables or symbols should be presented as simple text not included in filled-in boxes (MathType not needed).
If an equation is too long to fit into one line, it should be carried forward to the next line after an equal sign (=), a plus sign (+), a minus sign (‒), a multiplication sign (×), or another mathematical sign, provided that the sign is repeated at the beginning of the new line.
Numeric symbols and numerical factors should be explained immediately below the formula/equation in order of appearance. Sequential numbers that run through the whole text of the manuscript are added to the formulae and equations. Use Arabic numerals in brackets for numbering formulae and place each number at the right end of the corresponding line. For example:

A=a+b

(1)

A single formula/equation should be denoted as (1). In-text references to formula/equation numbers should be provided in Arabic numerals in brackets.

In English, decimal places in digits are separated with a full stop, and not with a comma (0.25 instead of 0,25). The reverse is true for Russian text (0,25 instead of 0.25).

IX. References

The authors are responsible for accuracy and completeness of the data they provide for the list of references. A reference list should include only indexed Russian and international sources, preferably published over the last 5–7 years —articles from scientific journals and collections (including online ones), monographs, and patents. The journal adheres to an adapted version of the Vancouver style. Other documents (including GOST standards, regulatory documents, and pharmacopoeial articles) should be cited in footnotes (see Footnotes).

International citation systems require that References should be included in the English-language part of the article. Accordingly, references should be made not only in the original language but also in the Latin (Roman) alphabet, according to official translations. Add an English translation of Russian references; add (In Russ.) at the end of each binary reference. The use of hyphenation for word breaks (especially DOIs) is prohibited, as this may impede correct indexing in databases.

Other recommendations:

References should be listed in the order they are first used in the text.
The number of references in the list depends on the publication type. However, the journal encourages including not more than 60 references per manuscript.
If there are fewer than four (4) authors, all of them should be mentioned in the bibliographic description. If there are more than four (4) authors, only the first 3 should be mentioned, and the rest should be indicated as et al.
There should be no commas between authors’ last names and their initials and no full stops after the initials, e.g. Smith WJ.
Give the names of journals, books, monographs, and collections in italic print.
Give full names of Russian journals; you may use official abbreviations/ truncations of English-language journals.
Bibliographic descriptions of journal articles should state the date of publication, volume and issue of the journal, and page numbers. The last page number should specify only the range that changes, e.g. 482–6). For example, 2025;22(1):271-9.
When describing a source, include its DOI; if none -EDN or PMID; no other identifiers are used. DOI is added as https://...

Formatting examples for references

Articles

Pecoraro C, Fioretti T, Perruno A, Klain A, Cioffi D, Ambrosio A, et al. De novo large deletions in the PHEX gene caused X-linked hypophosphataemic rickets in two Italian female infants successfully treated with burosumab. Diagnostics (Basel). 2023;13(15):2552.
https://doi.org/10.3390/diagnostics13152552

Engalycheva G.N., Syubaev R.D. WoE Analysis and Key Risk Factors in Preclinical Development of Medicinal Products: A Review. Safety and Risk of Pharmacotherapy. 2024;12(4):463-476. (In Russ.)
https://doi.org/10.30895/2312-7821-2024-12-4-463-476

Monographs

Johnson G, Hill-Smith I, Bakhai C, eds. The minor illness manual. 6th ed. New York: CRC Press; 2024.

Kovalskaya GN, Verlan NV, Mikhalevich EN, Kolmakova ES. Medicinal herbal preparations. Irkutsk: IGMAPO; 2023 (In Russ.). EDN: ETMNHW

Chapters of a monograph or a collected book

Maslova OV, Sen’ko OV, Stepanov NA, Efremenko EN. Biocatalytic synthesis of organic acids and plastics based on them. In: Varfolomeev SD, ed. Chemistry of biomass: biofuels and bioplastic. Moscow: Nauchny mir; 2017. P. 621–51 (In Russ.).

Materials of scientific conferences

28th European meeting on hypertension and cardiovascular protection. Barcelona; 2018.

Patents

Kornilova OG, Krivykh MA, Voropaev AA, Khusnatdinova приEA. Standard sample of the content of the prekallikrein activator in human blood products. Patent of the Russian Federation No. 2756159; 2021 (In Russ.).
EDN: WSWQGN

X. Footnotes

Footnotes are preferred for references to non-indexed sources:

thesis abstracts¹ and theses²
educational and instructional materials³
laws and regulations⁴ (including pharmacopoeial monographs)⁵
state standards (GOST)⁶
guidelines and recommendations⁷
information from websites⁸
statistical documentation⁹, scientific and technical documentation (including research and development reports¹⁰)
clinical guidelines¹¹
preprints¹²
datasets (published in repositories, not in peer-reviewed journals)¹³

General formatting requirements

Footnotes are made using the MS Word tool “References” → “Insert Footnote” (Arabic numerals). Add the original footnotes without translating them.
Authors’ commentaries are also given in the footnotes.
The footnotes are sequentially numbered, each having its unique number; when a source is mentioned again in the text, it is assigned a new sequential number. In other words, one and the same source may appear in footnotes as many times as needed, and be assigned different numbers (e.g. 1, 6, and 8).; if the information in a footnote repeats the information in the previous footnote, the authors may replace the full name of the source with Ibid.¹⁴
Several footnotes may be given for one reference.
One footnote may list several references.
If a manuscript contains the full official name of a document, information database, or another source, which allows for unambiguous identification of the source (for example, “the article analyses the provisions of Federal Law of the Russian Federation No. 61-FZ On Circulation of Medicinesof April 12, 2010), the authors need not include information about this source in footnotes, because the information provided in the text is sufficient.
For materials posted on the Internet and having no official bibliographic description, the footnotes should include the URL the page where the document is located; If the name of an official web site (of an organisation, database, register, etc.) is given in the text, the footnote may include only its URL (e.g. “according to the State Register of Medicinal Products”³).
If the bibliographic description, including the document number, allows for unambiguous identification of a document, the web address of the document should not be included.
Datasets published in peer-reviewed journals are cited as articles in the references.
The preprint must contain the date of posting on the server, as well as a note in square brackets that it is a preprint.
For preprints, at the stage of approval of the layout, the authors should check on the preprint server whether an article has been published based on it, and make the correct replacement.

Examples of footnotes

¹ ICH S6(R1) Preclinical safety evaluation of biotechnology-derived pharmaceuticals. ICH; 2011.
Guideline on process validation for finished products – information and data to be provided in regulatory submissions. EMA/CHMP/CVMP/QWP/BWP/70278/2012-Rev1,Corr.1. EMA; 2016.

²Efficacy and tolerance of naked DNA vaccine in patients with chronic B hepatitis (VAC-ADN). https://clinicaltrials.gov/ct2/show/NCT00536627

³Weight-of-Evidence Assessments: Unpacking New Guidance on Carcinogenicity Testing. February 1, 2023. https://premierconsulting.com/resources/blog/weight-of-evidence-assessments-unpacking-new-guidance-on-carcinogenicity-testing/
https://grls.rosminzdrav.ru

⁴ Heitmann S, Vandenberg JI, Hill AP. Assessing drug safety by identifying the axis of arrhythmia in cardiomyocyte electrophysiology [Preprint]. Posted 19.04.2023. bioRxiv. 537441. https://doi.org/10.1101/2023.04.19.537441

⁵ Andrei V. Ivanov (2025), “ADA Trastuzumab Additional Data”, Mendeley Data, V2, https://doi.org/10.17632/fvfp4htspn.2

⁶GOST R 56701-2015. Medicines for medical application. Guidance on non-clinical safety srtudies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. https://protect.gost.ru/document.aspx?control=7&id=202133

⁷ Guideline on process validation for finished products – information and data to be provided in regulatory submissions. EMA/CHMP/CVMP/QWP/BWP/70278/2012-Rev1,Corr.1. EMA; 2016. https://www.ema.europa.eu/en/process-validation-finished-products-information-data-be-provided-regulatory-submissions-scientific-guideline

⁸ Weight-of-Evidence Assessments: Unpacking New Guidance on Carcinogenicity Testing. February 1, 2023. https://premierconsulting.com/resources/blog/weight-of-evidence-assessments-unpacking-new-guidance-on-carcinogenicity-testing/

⁹ World health statistics 2023: monitoring health for the SDGs, Sustainable Development Goals. Geneva: World Health Organization; 2023. Licence: CC BY‑NC‑SA 3.0 IGO.https://www.who.int/publications/i/item/9789240074323

¹⁰ U.S. Investments in Medical and Health Research and Development, 2016-2020. https://www.researchamerica.org/wp-content/uploads/2022/09/ResearchAmerica-Investment-Report.Final_.January-2022-1.pdf

¹¹Guidelines for the Diagnosis and Management of Asthma. Full report 2007. U.S. Department of State and Human Services. https://www.nhlbi.nih.gov/sites/default/files/media/docs/EPR-3_Asthma_Full_Report_2007.pdf

¹²Heitmann S, Vandenberg JI, Hill AP. Assessing drug safety by identifying the axis of arrhythmia in cardiomyocyte electrophysiology [Preprint]. Posted 19.04.2023. bioRxiv. 537441. https://doi.org/10.1101/2023.04.19.537441

¹³ Andrei V. Ivanov (2025), “ADA Trastuzumab Additional Data”, Mendeley Data, V2, https://doi.org/10.17632/fvfp4htspn.2

¹⁴ Ibid.

XI. Additional information, ethical and other statements

Each block (if any) of this section should be provided in Russian and in English. All article types require the following sections: Funding and Disclosure (placed after Keywords), as well as Authors’ Contributions and Authors (after References). Other possible sections: Ethics Approval, Publication Informed Consent, Acknowledgements, and Declaration of Access to Benchmark Data and Algorithms.

External funding

If a grant has been awarded, it is important to specify the official name of the awarding organisation and include the grant number.

Example:

Funding. The study reported in this publication is a result of publicly funded research project No. 026-00020-21-00 and was supported by the Scientific Centre for Expert Evaluation of Medicinal Products (R&D reporting No. 124022200503-4).

Disclosure of potential conflicts of interest

The journal requires disclosing potential conflicts of interest using the standard 13-item ICMJE Disclosure Form for Potential Conflicts of Interest. Based on the completed forms, the authors should generate the final disclosure statement. If none of the authors has a potential conflict of interest, they should still include a statement to that effect.

Example:

Disclosure. P.P. Petrov has been a member of the Editorial Board of Safety and Risk of Pharmacotherapy since 2021. I.I. Ivanov is the copyright holder and developer of the literature monitoring automation software EV®. However, this does not influence their view and interpretation of the facts and provisions discussed in this article. The other authors declare no conflict of interest.

Authorship and authors’ contributions

The journal adheres to the authorship criteria outlined by the International Committee of Medical Journal Editors (ICMJE). The authors are individuals who fulfil all four (4) of the following criteria:

substantial contributions to the work conception or design;
acquisition, analysis, or interpretation of data for the work; AND
work drafting and/or substantive editing; AND
final approval of the version to be published; AND
agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

The journal encourages the authors to acknowledge contributors who played any other role in the preparation of the article than those outlined by the ICMJE. There are no requirements for using any particular international system for this. If the authors acknowledge contributions according to the CRediT (Contributor Roles Taxonomy) classification, including 14 roles, its tentative translation into Russian is provided here. The corresponding author is responsible for the co-operation between all authors on contribution details.

Examples:

Authors’ contributions. All the authors confirm that they meet the ICMJE criteria for authorship. The most significant contributions were as follows. Christina K. Kuznetsova, designed the study, controlled the main points of experiments, drafted and edited the manuscript. Pelageya P. Petrova designed the study and its methodology and edited the manuscript. Svetlana S. Sidorova planned and conducted the experiments, collected and analysed data, and drafted the manuscript. Taras T. Timofeev elaborated the study idea, planned the study, formulated the study aims and objectives, and critically revised the manuscript.

Acknowledgements

The authors may acknowledge individuals who contributed to the work but can not be considered authors according to the ICMJE criteria.
The authors may also acknowledge organisations that supported them (e.g. by providing premises, materials, reagents, animals for the study, access to patients, etc.).
It is important to specify names, companies, and organisations and refrain from acknowledging irrelevant and unspecific contributions (e.g. expressing gratitude to some anonymous journal reviewers).
When mentioning someone in acknowledgements, the authors should ask for permission to mention them. The authors will deal with all claims against the journal from third parties regarding unlawful mentions by the authors.

Example:

Acknowledgments. The authors express their gratitude to the staff of the departments that recruited patients and personally to the heads of these departments of City Clinical Hospital No. X, I.I. Ivanov, Dr. Sci. (Med.), P.P. Petrov, and S.S. Sidorov, Dr. Sci. (Med.).

Ethics approval

The full name of the ethics committee and details of the approval document (number and date) should be given for interventional studies. Please omit this section in articles on other studies.

Examples:

Ethics approval. According to the authors, the analysis was based on previously published anonymised data, and the study did not involve direct participation of human subjects. Hence, this study is exempt from ethics approval.

Ethics approval. The protocol of this observational clinical study was approved by the local ethics committee of the City Clinical Hospital No. X, Moscow Department of Healthcare (meeting minutes No. 29 of 21 October 2024).

Informed consent for publication

This section is included only when it is applicable or when the article is a case report.
The section and consent for publication are required if the manuscript contains data that provide for patient identification (e.g. medical history and photographs).
If a clinical observation article does not require consent, this section should state “Not required”.
Only in exceptional cases where no legal representatives can be found and the case is essential to medical practice, it may be published without consent, but the authors should clearly explain the lack of consent and indicate that every effort has been made to obtain it.
A patient’s consent usually states that personal data will be anonymised, which should be done in the manuscript (e.g. by partly closing the patient’s face); it is not necessary to provide consent forms to the journal.
Please see Ethical Oversight for more details.

You may find the recommended consent form here.

Example:

Consent for publication. The patient gave informed consent for processing of their personal data, as well as for anonymised publication of their medical data and photographs.

Data access and algorithmic transparency statement

The journal does not require, but encourages, the authors to include this section in their manuscripts, in accordance with its Research Data Sharing and Reproducibility policy.

The journal recommends using the following template for making a statement about providing access to source data.

Item No.	*Data status*	Example (Data Access)
1.	Data are openly available in a public repository that provides DOIs	The data that support the findings of this study are openly available in [repository name, e.g. Figshare; address, e.g. URL/DOI; reference number]. Data supporting the findings of this study are publicly available at Mendeley Data, V1, https://doi.org/10.17632/2z3dmg4y5f.1
2.	Data are available in the article or as additional materials online	The authors confirm that the data that support the findings of this study are available in the article [and/or] additional materials in the online version of the article
3.	Data are embargoed for commercial reasons	The data that support the findings of this study will be available in [repository name] at [URL/DOI] following an embargo of [e.g. 6 months] from the date of publication to allow for commercialisation of research findings.
4.	Data are available only upon request to a limited audience for privacy reasons	The data that support the findings of this study can be obtained from the corresponding author [initials] upon request. The data are not publicly available because of [restrictions, e.g. they contain information that could compromise the privacy of research participants].
5.	Data are subject to third-party restrictions	The data that support the findings of this study are available [upon a third party’s permission]. Restrictions apply to the availability of these data, which were used under license for this study. The data are available [from the authors / URL] with the permission of [third party].
6.	Data are available upon request	The data that support the findings of this study are available from the corresponding author [author initials] upon reasonable request.
7.	Data are not available for [ethical/legal/ commercial/other] reasons	The research data are not available in view of the nature of the research [ethical/legal/commercial constraints].

Об авторах / Authors

This section should include the authors’ full names (Ivan I. Ivanov), academic degrees, titles, and ORCIDs (as https://orcid.org/0000-0000-0000-0000).

XII. Recommended resources for manuscript preparation

Supporting documents

Cover letter

ICMJE form on potential conflicts of interest

Templates

Original article template
Case report template
Review template

Checklists and recommendations

Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (Updated January 2025)

Editing and Publishing Process Flowchart

Section revision date: 29.09.2025

Submission Preparation Checklist

As part of the submission process, authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to these guidelines.

Manuscripts are accepted if they have not been published or submitted for publication elsewhere (or this fact is explained in the Commentaries for the editor).
The materials have to be submitted in the OpenOffice, Microsoft Word, RTF, or World Perfect format.
Internet links are provided as a complete URL, wherever possible.
Manuscript text should comply with the Author Guidelines.
The article does not include the materials prohibited for publication, according to the current regulatory documents.
All the authors confirm that they meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship.
All the authors give their consent for processing and dissemination of their personal data according to Art. 6, Russian Federal Law No. 152-FZ of 27 July 2006 “On Personal Data” (including surname, name, patronymic, academic title and status, affiliation, and job/ study address) in order to publish the submitted article in the Journal.

Copyright Notice

Authors who have their articles published in this journal agree to the following terms:

The authors retain copyright for their work and grant the journal with the right of first publication under Creative Commons Attribution Licensethat allows others to share the work if they reference the authors and the original publication.
The authors may post preprints and postprints and study data of their articles in institutional or public repositories in line with the journal’s Preprint and Postprint Deposition

Privacy Statement

Specified names and email addresses will be used solely for the purposes of this journal and will not be shared with other individuals/organisations for any other purposes.

ISSN 2312-7821 (Print)
ISSN 2619-1164 (Online)

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

User

Safety and Risk of Pharmacotherapy

Submissions

Online Submissions

Author Guidelines

I. Submission

II. Manuscript submission and interaction with the journal

III. Article types

IV. Structure of bibliographic data / metadata

V. Contents of the main text sections

VI. Text layout and formatting

VII. Tables and figures

VIII. Mathematical formulae, equations, and symbols

IX. References

X. Footnotes

XI. Additional information, ethical and other statements

XII. Recommended resources for manuscript preparation

Submission Preparation Checklist

Copyright Notice

Privacy Statement

Cookies policy